FH

LIB Therapeutics Announces Positive Results from LIBerate-HR Study: A 52-Week, Placebo-Controlled Registration-Enabling Trial of Lerodalcibep at Late-Breaking Session at American College of Cardiology 2024

Retrieved on: 
Monday, April 8, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Week, Temperature, Cardiovascular disease, PCSK9, CVD, ADAS, FH, Patient, Travel, Female, Refrigeration, OLE, MBBS, Marketing, European Medicines Agency, American College, Therapy, Liberation, ITT, Safety, Food, ACC, Apolipoprotein B, Apolipoprotein, Pharmaceutical industry

Patients were randomized 2:1 to a single 300 mg (1.2 mL subcutaneous) once-monthly dose of Lerodalcibep or placebo for 52 weeks.

Key Points: 
  • Patients were randomized 2:1 to a single 300 mg (1.2 mL subcutaneous) once-monthly dose of Lerodalcibep or placebo for 52 weeks.
  • Of 478 participants in the base LIBerate-HeFH trial, 421 (88%) continued into the OLE trial: 281 patients on Lerodalcibep and 140 on placebo.
  • All participants received open-label Lerodalcibep 300 mg in a subcutaneous 1.2 mL once-monthly dose starting immediately upon completion of the base trial.
  • After 48 weeks of OLE treatment, mean % LDL-C reductions with Lerodalcibep from baseline in the base trial was 48.5% (ITT population).

Retail Clinic Utilization Increased 202 Percent Nationally from 2021 to 2022, according to Seventh Annual FAIR Health Report

Retrieved on: 
Tuesday, March 26, 2024
Abdominal ultrasonography, COVID-19, FH, Patient, Policy, Radiology, ASC, FAIR, Hospital, Pathology, ERS, Medicine, E&M

NEW YORK, March 26, 2024 /PRNewswire/ -- Retail clinic utilization increased 202 percent nationally from 2021 to 2022, and emergency room (ER) utilization increased 138 percent.1 Retail clinics and ERs had the greatest increases in utilization among the places of service studied—which also included urgent care centers, telehealth and ambulatory surgery centers (ASCs)—in a new FAIR Health white paper containing the seventh annual edition of FH® Healthcare Indicators and FH® Medical Price Index. Like the previous editions, this year's edition of FH Healthcare Indicators and FH Medical Price Index is intended to provide perspective for all healthcare stakeholders in a rapidly changing healthcare environment.

Key Points: 
  • Focusing on alternative places of service and ERs, FH Healthcare Indicators evaluate changes in utilization, geographic and demographic factors, diagnoses, procedures and costs.
  • Among the other key findings:
    ASC utilization increased 88 percent nationally from 2021 to 2022; urgent care center utilization increased 43 percent and telehealth 8 percent in the same period.
  • Telehealth accounted for 3.9 percent of medical claim lines, urgent care centers 2.1 percent, ASCs 1.1 percent and retail clinics 0.2 percent.
  • The pathology and laboratory charge amount index increased four percent, while the surgery charge amount index increased three percent.

Viega LLC Announces Andreas Reger as New CEO

Retrieved on: 
Thursday, March 21, 2024
Universidad, Growth, Supervisory board, Category:Medwell Journals academic journals, Business administration, FH, Viega, Master of Business Administration, International business, Brettschneider, Colorado State University, Management

BROOMFIELD, Colo., March 21, 2024 /PRNewswire/ -- Viega LLC, an industry leader in press technology, recently announced the appointment of Andreas Reger as the new President and Chief Executive Officer (CEO), effective on April 1.

Key Points: 
  • BROOMFIELD, Colo., March 21, 2024 /PRNewswire/ -- Viega LLC, an industry leader in press technology, recently announced the appointment of Andreas Reger as the new President and Chief Executive Officer (CEO), effective on April 1.
  • Reger will replace Markus Brettschneider, who was recently appointed as the new Global CEO for Viega Group, effective September 2024.
  • Andreas has significant experience leading growing businesses and ensuring that growth benefits all stakeholders – customers, employees, communities and our industry," said Markus Brettschneider, current President and CEO of Viega LLC.
  • Reger joins Viega LLC from BBB Industries, the global market leader in sustainable automotive remanufacturing, where he served as the President of the Undercar Business Unit.

Tecumseh Unveils Enhanced Portfolio to Comply with Lower GWP Standards at CMPX 2024

Retrieved on: 
Thursday, March 14, 2024
UL, HG, Tecumseh Products, ANN, Argus, ALX, Kigali Amendment, TC, College of Engineering (KNUST), FH, ASHRAE, Hydrofluorocarbon, Refrigeration, R-32, ARGUS, VS, RG, AJ2, AE2

ANN ARBOR, Mich. , March 14, 2024 /PRNewswire-PRWeb/ -- Tecumseh Products Company, a pioneering force in compressor and refrigeration systems, is set to present its diverse product range geared towards addressing the ongoing global industry requirements for a more sustainable future at the CMPX Expo 2024. In alignment with the Kigali Amendment, which calls for a gradual reduction in the use of HFCs globally, Tecumseh will showcase reliable R-290 reciprocating compressors and A2L classified solutions tailored for commercial refrigeration and some specific heat pump applications. Additionally, the company will introduce expanded Argus condensing units designed to meet heightened demands for Walk-In Cooler and Freezer applications.

Key Points: 
  • Additionally, the company will introduce expanded Argus condensing units designed to meet heightened demands for Walk-In Cooler and Freezer applications.
  • Tecumseh proudly introduces two standout rotary compressor offerings, the RG and HG compressors, now compatible with R-454B, with an anticipated expansion of R-32 models in late 2024.
  • In the commercial refrigeration sector, Tecumseh is gearing up its system offerings to function with R-454C and R-455A for compressors exceeding 15cc displacement.
  • Following the updated UL standards in late 2023, R-290 refrigeration equipment will now be permitted a higher charge limit beyond 150g.

Auction house im Kinsky: Auction of the year with Klimt's "Portrait of Fräulein Lieser": Live feed and news feed offers for TV and online streaming

Retrieved on: 
Tuesday, March 12, 2024
FH, Sale, News, Exclusivity

How high will the sale price climb at the auction house im Kinsky?

Key Points: 
  • How high will the sale price climb at the auction house im Kinsky?
  • We provide the live feed from Vienna as a satellite downlink and stream which you can use live or in news coverage.
  • The auction house im Kinsky will present a rediscovered exquisite work of Austrian Modernism as part of the exclusive special auction on 24 April 2024.
  • This portrait of a lady from Gustav Klimt's late creative period has been missing until now and its rediscovery has become a worldwide sensation.

Auction house im Kinsky: Auction of the year with Klimt's "Portrait of Fräulein Lieser": Live feed and news feed offers for TV and online streaming

Retrieved on: 
Tuesday, March 12, 2024
FH, Sale, News, Exclusivity

How high will the sale price climb at the auction house im Kinsky?

Key Points: 
  • How high will the sale price climb at the auction house im Kinsky?
  • We provide the live feed from Vienna as a satellite downlink and stream which you can use live or in news coverage.
  • The auction house im Kinsky will present a rediscovered exquisite work of Austrian Modernism as part of the exclusive special auction on 24 April 2024.
  • This portrait of a lady from Gustav Klimt's late creative period has been missing until now and its rediscovery has become a worldwide sensation.

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Retrieved on: 
Monday, March 11, 2024
FDA, Gene, Patient, Regeneron Pharmaceuticals, FH, Parent, Alirocumab, Ageing, Diet, Pharmaceutical industry

“Many children with heterozygous familial hypercholesterolemia (HeFH) are able to substantially improve their LDL-C (bad cholesterol) with currently available therapies.

Key Points: 
  • “Many children with heterozygous familial hypercholesterolemia (HeFH) are able to substantially improve their LDL-C (bad cholesterol) with currently available therapies.
  • Familial hypercholesterolemia (FH) is an inherited condition caused by mutations in one of several genes that control how the body processes cholesterol, which can lead to very high levels of LDL-C (bad cholesterol).
  • Praluent is approved to treat both children and adults with HeFH and adults with HoFH.
  • Patients were randomized to receive Praluent (N=101) or placebo (N=52) every two or four weeks in two consecutive cohorts.

Planforge Announces Free Access to Standards-Based PPM Tool for Higher Education

Retrieved on: 
Thursday, March 7, 2024
Education, Data Management, Technology, Software, Continuing, University, Transfer, Student, Multimedia, PPM, Curriculum, Applied science, School, IPMA, Organization, FH, Partnership

As a result, the importance of professional project management training in higher education has increased significantly in recent years.

Key Points: 
  • As a result, the importance of professional project management training in higher education has increased significantly in recent years.
  • View the full release here: https://www.businesswire.com/news/home/20240307875210/en/
    Planforge provides universities with free access to standards-based PPM tool (Photo: Business Wire)
    Planforge , a leading provider of project and portfolio management (PPM) software, is addressing this challenge with its newly launched Education Partner Program , offering students free access to its platform.
  • The partnership provides schools and universities with unlimited, free access to Planforge's on-premises PPM software as well as limited, free on-request access to the vendor's cloud platform based on available resources.
  • The Department of Accounting and Controlling uses Planforge for a more practice-oriented education of all students attending IPMA-based project management courses.

LetsGetChecked Launches myGeneticScreen, a Genetic Testing Service Designed to Deliver Personalized, Actionable Insights into Predisposition for Inherited Cancers and Cardiovascular Diseases

Retrieved on: 
Wednesday, February 21, 2024
Medical Devices, Genetics, Health Technology, Telemedicine, Virtual Medicine, Cardiology, Biotechnology, Health, General Health, Oncology, Genetic counseling, Cardiovascular disease, FACMG, Hereditary nonpolyposis colorectal cancer, Ovarian cancer, Risk, Disease, Patient, Genetic testing, HBOC, Gene, Knowledge, Genomics, CDC, FH, Mortality, Familial hypercholesterolemia, Cancer

LetsGetChecked, a global healthcare solutions company, announced today the launch of myGeneticScreen, a genetic testing service designed to provide patients with valuable and actionable insights into their predisposition for certain hereditary conditions with end-to-end support, including personalized health reports and access to genetic counseling.

Key Points: 
  • LetsGetChecked, a global healthcare solutions company, announced today the launch of myGeneticScreen, a genetic testing service designed to provide patients with valuable and actionable insights into their predisposition for certain hereditary conditions with end-to-end support, including personalized health reports and access to genetic counseling.
  • This addition to LetGetChecked’s genetics portfolio strengthens the company’s commitment to empowering people with accessible health information and care to live longer, happier lives.
  • Using a saliva specimen, myGeneticScreen analyzes 11 genes associated with three conditions recommended by the Centers for Disease Control and Prevention (CDC) as actionable Tier 1 conditions.
  • Offering a best-in-class experience, the genetic testing service includes pre- and post- genetic counseling.

Access to Prescribed PCSK9 Inhibitors Remains a Significant Barrier Leaving Patients at Risk for Heart Attacks and Strokes

Retrieved on: 
Tuesday, February 20, 2024
Health, Hospitals, Other Health, General Health, Pharmaceutical, Cardiology, Biotechnology, Stroke, Research, PCSK9, Multimedia, Cardiovascular disease, Circulation, Splenic infarction, Risk, Patient, Apolipoprotein, Atherosclerosis, FH, Prescription, Pharmaceutical industry

Since 2019, PCSK9i have had a label expansion; positive results from major outcomes trials and large studies showing the use of PCSK9 inhibitors reducing cardiac events; a 60% price reduction on PCSK9i and established clinical practice guidelines all of which were supposed to improve utilization, yet access is still a barrier leaving patients at risk for heart attacks and strokes.

Key Points: 
  • Since 2019, PCSK9i have had a label expansion; positive results from major outcomes trials and large studies showing the use of PCSK9 inhibitors reducing cardiac events; a 60% price reduction on PCSK9i and established clinical practice guidelines all of which were supposed to improve utilization, yet access is still a barrier leaving patients at risk for heart attacks and strokes.
  • View the full release here: https://www.businesswire.com/news/home/20240220789784/en/
    The burden of cardiovascular disease, driven largely by atherosclerosis, is increasing in the United States.
  • While statins are the first line of treatment, they may not lower LDL-C enough for high-risk patients.
  • The 2018 ACC/AHA Multi-society Guidelines on the Management of Blood Cholesterol recommended the use of PCSK9i for appropriate patients.